In another blow to the potential uptake of Biogen, Inc.’s and Eisai Co., Ltd.'s controversial new drug for Alzheimer’s disease, the US Department of Veterans Affairs has decided it will not cover Aduhelm on its centralized drug formulary or allow the manufacturers to promote the drug to VA clinicians because it has an unfavorable risk/benefit profile.
“We did not add it to the VA national formulary based on the risk of significant adverse drugs events and...







